PharmaEngine

智 擎 生 技 製 藥

4Q 2023 Financial Results

2024/03/05

Disclaimer

PharmaEngine
智 擎 生 技 製 藥

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as 'believes,' 'expects,' 'anticipates,' 'projects,' 'intends,' 'should,' 'seeks,' 'estimates,' 'future,' or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. Pricing and product initiatives of competitors
2. Legislative and regulatory developments and economic conditions
3. Delay or inability in obtaining regulatory approvals or bringing products to market
4. Fluctuations in currency exchange rates and general financial market conditions
5. Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products
6. Increased government pricing pressures
7. Interruptions in production
8. Loss of or inability to obtain adequate protection for intellectual property rights
9. Litigation
10. Loss of key executives or other employees
11. Adverse publicity and news coverage

PharmaEngine cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. PharmaEngine undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that PharmaEngine 's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of PharmaEngine, Inc.

Agenda

1. 2023 Operational Highlights
2. 2023 Operational Overview
3. Research and Development
   - ONIVYDE®
   - PEP07
4. Vision for 2024
5. Q&A

PharmaEngine
智 擎 生 技 製 藥

2023 Operational Highlights-
Keep Delivering Sustainable Growth and Enhanced Value

PharmaEngine 智擎生技製藥

Commercial

ONIVYDE® market and new indication expansion

1. Taiwan FDA sNDA submission (PharmaEngine)
2. EMA Type II Variation submission (Servier)
3. **US FDA sNDA approval received on February 13, 2024 (IPSEN)**

Pipeline

New project R&D progress accelerated

1. Phase 1 clinical studies of PEP07 for hematologic and solid tumor cancers continue.
2. Multiple projects meet expectations with external AI/CADD collaboration
3. >20% regular operation revenue as R&D expense

Operation

Operation with a sustainable growth

1. Approved by the Ministry of Economic Affairs as a “Biotech and Pharmaceutical Company”
2. FY 2023 cash and cash equivalents and current financial assets at amortised cost: NT$36.3 bn
3. Completed the scope 1&2 emissions data collection, analysis and third-party assurance

2023 Operational Overview



Sales and Royalties Drives Long-term Growth

NT$(000)

Items / Year	2017	2018	2019	2020	2021	2022	2023 YTD YoY (%)
Taiwan Sales	40,651	87,384	180,389	214,828	235,469	277,594	278,547 (0%)
Royalties from Europe and Asia	63,526	109,825	133,651	271,584	419,366	376,789	426,652 (+13)
Milestone	749,500	96,221	0	569,600	0	0	62,470 (+100%)
Total	853,677	293,430	314,040	1,056,012	654,835	654,383	767,669 (+17%)

2023 Financial Results

PharmaEngine 智擎生技製藥

NT$(000)	FY2023	1Q-3Q 2022	Amount Change	% Change
Operating revenue	767,669	654,383	113,286	17%
Operating costs	48,697	49,699	(1,002)	(2%)
Gross profit	718,972	604,684	114,288	19%
Sales expenses	38,538	45,104	(6,566)	(15%)
G&A expenses	92,970	94,960	(1,990)	(2%)
R&D expenses	310,281	181,881	128,400	71%
Total operating expenses	441,789	321,945	119,844	37%
Operating income	277,183	282,739	(5,556)	(2%)
Total non-operating income and expenses	60,791	109,726	(48,935)	(45%)
Income before income tax	337,974	392,465	(54,491)	(14%)
Income tax expense	63,324	73,682	(10,358)	(14%)
Profit for the period	274,650	318,783	(44,133)	(14%)
EPS(NT$)	1.91	2.22	(0.31)	(14%)

Research and Development

- ONIVYDE® 1L PDAC NDA submission status
- First patient dosed in PEP07 phase 1 for hematologic cancers
- PEP07 phase 1 for solid cancer approved by TFDA
- Multiple projects in collaboration with external AI/CADD

Development of Pancreatic Cancer Therapy in Taiwan



Taiwan PDAC Therapy Market Analysis



PEP07 – Potential Best in Class CHK1 Inhibitor

PEP07 is a brain penetrating oral inhibitor which is more potent and selective than the competitors.

	Drug	Stage	Potency	Selectivity	Oral Bioavailability
Acrivon (Eli Lily)	Prexasertib	Ph II			
Genetech	GDC-0575	Discontinued			
GSK (Sierra Oncology)	SRA-737	Ph I / II (Complete)			
Esperas Pharma	LY2880070	Ph I / II (Complete)			
PharmaEngine	PEP07	Ph I			

Excellent Good Fair Poor Unknown

PEP07 for Potential Combination Therapies



Synergistic effect verified in PEP07

Additive effect observed in PEP07

In vitro Combo Treatment

SoC agents	Indication	Cell line
Ara-C	AML	MV4-11 / THP-1
Gemcitabine	NSCLC	NCI-H1703
5-Fu	Esophagus	KYSE-270
5-Fu	Stomach	MKN-45, SNU-16, SNU-5,
5-Fu	CRC	DLD-1, HT-29, SW480
TMZ	Brain	IMR-32
Sorafenib	RCC	A498

Green: Synergism; **Blue: Additivity**

Clinical Trial Designs and Indications Guidance

Targeting the DNA Damage Response for Anti-Cancer Therapy 241-276, 2018

PEP07 Early-Stage Clinical Development Strategy

dose escalation/expansion in **AML and MCL**

dose escalation/expansion in selected hematologic cancer, e.g., **AML or MCL**

dose escalation/expansion in advanced or metastatic **solid tumor**

dose escalation/expansion in selected **solid tumors**

Preclinical biomarker study is ongoing for further design of clinical trials.

Vision for 2024



Virtual Pharmaceutical Company Business Model

PharmaEngine 智擎生技製藥



Pipeline Portfolio Focus on Precision Oncology

Program		Indications	Lead	Preclinical	Phase I	Phase II	Phase III	Approval	Commercial Rights	Partner
ONIVYDE® (liposomal irinotecan)		2L PDAC						Approval	EU/Asia	IPSEN Innovation for patient care
		1L PDAC					Primary Endpoint met (2022/11)			
DDR	PEP07 (CHK1i)	AML/Solid Tumors							Global	Sentinel ONCOLOGY
DNA Damage Response	PEP09	Undisclosed							Global	Undisclosed
	PEP10	Undisclosed (Predictive Biomarker)							Global	PEI Owned
Precision Oncology	PEP08	Undisclosed (Predictive Biomarker)							Global	PEI Owned

DDR: DNA Damage Response (BRCA ½, CHK ½, Wee1, etc…)

Continuous Advancement of Pipelines and ESG Activities



PharmaEngine

智 擎 生 技 製 藥

NAPOLI-3

A randomized, Open Label Phase 3 Study of Liposomal Irinotecan + 5-FU/LV + Oxaliplatin (NALIRIFOX) versus Nab-Paclitaxel + Gemecitabine in Treatment-naïve Patients with Metastatic Pancreatic Ductal Adenocarcinoma

PharmaEngine 智擎生技製藥

- NALIRIFOX (n = 383) vs. Gem + NabP (n = 387), 770 patients enrolled
- Study endpoints:
  - Primary endpoint – OS (Overall Survival)
  - Secondary endpoints – PFS (Progression Free Survival), ORR (Objective Response Rate)
- First Patient Enrolled: Feb. 2020; Data cut-off: July 23, 2022
- Topline results presented in 2023 ASCO GI







- Conclusion
  - The NALIRIFOX regimen met its primary endpoint demonstrating a statistically significant improvement in OS of 11.1 in months compared to 9.2 months for patients treated with Gem + NabP (HR 0.83 [95% CI 0.70–0.99]; p=0.04).
  - The trial met its secondary endpoint showing patients treated with NALIRIFOX had a statistically significant improvement in mPFS of 7.4 months versus 5.6 months for Gem + NabP (p < 0.0001); ORR was 41.8% (36.8%-46.9%; 95% CI) for patients treated with the NALIRIFOX versus 36.2% with Gem + NabP (31.4%-41.2%; 95% CI).
  - Overall, the safety profile of NALIRIFOX in NAPOLI 3 was manageable. No new safety concerns with the NALIRIFOX regimen were identified.